Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction

BACKGROUND: Androgen ablation is the first-line therapy for patients with metastatic prostate cancer (CaP). However, castration resistance will eventually emerge. In the present study, we have investigated the role of bone morphogenetic protein-6 (BMP-6) in the development of castration-resistant pr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lee, G T, Kang, D I, Ha, Y-S, Jung, Y S, Chung, J, Min, K, Kim, T H, Moon, K H, Chung, J M, Lee, D H, Kim, W-J, Kim, I Y
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2014
Matèries:
Molecular Diagnostics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3960605/
https://ncbi.nlm.nih.gov/pubmed/24518599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.23
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars